Overview
Lymphoid neoplasms encompass a diverse group of malignancies arising from lymphocytes, including leukemias and lymphomas, often characterized by dysregulated proliferation and immune dysregulation. These conditions require precise diagnosis and tailored management strategies to address cytopenias, immune-related adverse effects, and specific therapeutic challenges like those posed by Bruton's tyrosine kinase inhibitors (BTKis) and CAR-T cell therapies.Diagnosis
Clinical Presentation: Symptoms vary but often include lymphadenopathy, splenomegaly, and systemic symptoms like fever and weight loss.
Laboratory Tests: Complete blood count (CBC) abnormalities, including cytopenias (anemia, thrombocytopenia, neutropenia), are common 2.
Imaging: CT scans, PET scans to assess extent and involvement of lymphoid tissues.
Histopathology: Bone marrow biopsy and lymph node biopsy for definitive diagnosis.
Flow Cytometry: Essential for identifying specific cell surface markers characteristic of different lymphoid neoplasms.
Genetic Testing: FISH, PCR for specific genetic alterations (e.g., IGH translocations in CLL).Management
First-Line Treatments:
- BTK Inhibitors: Ibrutinib, acalabrutinib, zanubrutinib for certain B-cell malignancies, monitoring for bleeding risks, especially when combined with anticoagulants or antiplatelet agents 1.
- CAR-T Cell Therapy: Tisagenlecleucel, axicabtagene ciloleucel for relapsed/refractory B-cell lymphomas and leukemias, closely monitored for cytokine release syndrome and cytopenias 3.
Adjunctive Treatments:
- Supportive Care: Management of cytopenias with transfusions, growth factors (e.g., G-CSF for neutropenia).
- Infection Prophylaxis: Antimicrobials for febrile neutropenia and other infections 2.Special Populations
Pediatrics: Limited data; CAR-T therapies are increasingly explored with careful monitoring of long-term effects 3.
Elderly: Higher risk of cytopenias and complications; tailored dosing and close monitoring recommended 2.
Comorbidities: Increased vigilance for adverse reactions, particularly bleeding risks with BTK inhibitors in patients on anticoagulants 1.Key Recommendations
Monitor Bleeding Risks Closely with BTK Inhibitors: Regular assessment and management of bleeding risks, especially in patients on anticoagulants or antiplatelet therapy (Evidence: Moderate) 1.
Aggressive Supportive Care for Cytopenias Post-CAR-T Therapy: Implement proactive management strategies including transfusions and growth factors to mitigate severe cytopenias (Evidence: Moderate) 2.
Close Surveillance for Cytokine Release Syndrome Post-CAR-T Infusion: Early recognition and intervention are crucial for managing cytokine release syndrome (Evidence: Moderate) 3.References
1 Qu H, Jia Y, Liu Z, Li Z, Zhao X, Wu Z et al.. A pharmacovigilance study of Bruton's tyrosine kinase inhibitors: a multidimensional analysis based on FAERS and VigiBase. Frontiers in immunology 2025. link
2 Xia Y, Zhang J, Li J, Zhang L, Li J, Fan L et al.. Cytopenias following anti-CD19 chimeric antigen receptor (CAR) T cell therapy: a systematic analysis for contributing factors. Annals of medicine 2022. link
3 Fusaroli M, Isgrò V, Cutroneo PM, Ferrajolo C, Cirillo V, Del Bufalo F et al.. Post-Marketing Surveillance of CAR-T-Cell Therapies: Analysis of the FDA Adverse Event Reporting System (FAERS) Database. Drug safety 2022. link